Pfizer Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDPfizer Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 65), indicating performance broadly in line with the market. Earnings contraction of 5% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $27.08 | +2.12% | ABOVE |
| 50 SMA | $26.09 | +5.98% | ABOVE |
| 100 SMA | $25.61 | +7.97% | ABOVE |
| 150 SMA | $25.31 | +9.24% | ABOVE |
| 200 SMA | $25.03 | +10.47% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PFE in an uptrend right now?
PFE has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, PFE is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is PFE overbought or oversold?
PFE's RSI (14) is 55. The stock is in neutral territory, neither overbought nor oversold.
Is PFE outperforming the market?
PFE has a Relative Strength (RS) Rating of 65 out of 99. PFE is performing about average compared to the market.
Where is PFE in its 52-week range?
PFE is trading at $27.65, which is 99% of its 52-week high ($27.94) and 96% above its 52-week low ($20.92).
How volatile is PFE?
PFE has a Beta of 0.50 and 52-week volatility of 27%. It's less volatile than the S&P 500 - generally more stable.